Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2024-05-13 Regulatory Filings
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Outstanding 98.6% Success Rate in Striate Implant Study 3 pages 281.3KB
Regulatory Filings Classification · 90% confidence The document is a press release announcing the results of a post-market clinical study for Orthocell's Striate+ dental implant membrane. It provides detailed clinical study results, success rates, market potential, and product information. There is no indication that this is a financial report, regulatory filing, or management discussion. The content focuses on clinical study outcomes and product performance rather than financial data or corporate governance. It is not a report publication announcement since it contains substantive study data and analysis. The document is best classified as a Regulatory Filings (RNS) type because it is a general regulatory announcement about clinical study results and product performance, which does not fit into other specific financial or corporate filing categories.
2024-05-13 English
Compelling 85% Success Rate Remplir Study now published 3 pages 261.1KB
Regulatory Filings Classification · 90% confidence The document is a press release announcing the publication of clinical study results for Orthocell's Remplir nerve repair product in a peer-reviewed medical journal. It details the study objectives, results, and significance, but does not contain financial statements, regulatory filings, or detailed investor presentations. It is not an annual or interim report, earnings release, or management discussion. The document is primarily a public announcement of clinical study results and publication, aimed at investors and the public. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. Given the nature of the content as a public announcement of study results and publication, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories. Confidence is high as the document is clearly a press release and not a formal financial or regulatory report.
2024-04-29 English
Securities Trading Policy 8 pages 314.3KB
Governance Information Classification · 95% confidence The document is titled 'Securities Trading Policy' for Orthocell Limited and details rules and restrictions on insider trading, blackout periods, authorisation procedures for trading by directors and senior management, and compliance with the Corporations Act and ASX Listing Rules. It is a policy document governing insider trading and securities dealings by company insiders rather than a financial report, regulatory filing, or announcement. It does not contain financial statements, earnings data, or shareholder meeting information. It is not a report publication announcement or certification. The content fits best under a governance-related document describing internal rules and compliance policies for securities trading by insiders. Therefore, the most appropriate classification is Governance Information (CGR).
2024-04-23 English
Change of Director's Interest Notice-John Van Der Wielen 2 pages 220.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares and options held before and after the change, the nature of the change (on-market purchase), and confirms no trading during a closed period without clearance. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document length is 3739 characters, which is consistent with a detailed notice rather than a full financial report. Therefore, the correct classification is Director's Dealing (DIRS).
2024-04-23 English
Change of Director's Interest Notice-John Van Der Wielen 2 pages 220.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares and options held before and after the change, the nature of the change (on-market purchase), and confirms no trading during a closed period without clearance. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document length is 3789 characters, which is typical for such notices. Therefore, the correct classification is DIRS.
2024-04-15 English
Orthocell receives $3.05m R&D tax incentive refund 2 pages 213.5KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Orthocell has received a $3.05 million R&D tax incentive refund. It also mentions recent fundraising activities, board restructuring, and strategic updates. The content focuses on financial and operational updates but does not contain detailed financial statements or comprehensive financial performance data. The document is relatively short (6,241 characters) and reads as an announcement rather than a full financial report. There is no indication that this is an earnings release with key financial highlights, nor is it a detailed investor presentation or management report. It is primarily a capital/financing update related to cash reserves and funding status. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-04-14 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.